Patients with the rs7270101 CC genotype and chronic hepatitis C may have a decreased risk of anemia when treated with peg interferon alfa-2b and ribavirin as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other clinical and genetic factors may influence the risk of anemia.